Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Sosei Heptares

This page shows the latest Sosei Heptares news and features for those working in and with pharma, biotech and healthcare.

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs

Latest news

  • Pfizer’s alliance with Sosei Heptares bears first fruit Pfizer’s alliance with Sosei Heptares bears first fruit

    The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly

  • Pfizer signs high-level deal with GPCR specialist Heptares Pfizer signs high-level deal with GPCR specialist Heptares

    Pfizer's strategic-level deal with Sosei subsidiary Heptares will see the UK firm apply its technologies to engineer stabilised target GPCR proteins - selected by Pfizer - that will be used to ... biologics drugs - and will pay up to $189m per project to

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify

  • Deal Watch March 2017 Deal Watch March 2017

    rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Quick links

Infographics

Multimedia